Clinical Trial Update: FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting on FR901228 for relapsed or refractory multiple myeloma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma | Phase 2 | Status: COMPLETED